Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments
A Ramírez-Chacón, S Betriu-Méndez… - Frontiers in …, 2022 - frontiersin.org
Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments
for multiple malignancies. Despite their clinical success, there is scientific evidence of the …
for multiple malignancies. Despite their clinical success, there is scientific evidence of the …
[HTML][HTML] Autoantibodies against SUMO1-DHX35 in long-COVID
L Thurner, N Fadle, E Regitz, KD Preuss… - Journal of Translational …, 2022 - Elsevier
Long COVID is a collection of symptoms as a late sequelae of SARS-CoV-2 infection. It often
includes mental symptoms such as cognitive symptoms, persisting loss of smell and taste, in …
includes mental symptoms such as cognitive symptoms, persisting loss of smell and taste, in …
Identification of novel prognostic autoantibodies in diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and …
L Dai, H Chen, Q Tan, Y Wang, L Li, N Lou, G Fan… - Cancer, 2024 - Wiley Online Library
Background R‐CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and
prednisone) is a standard first‐line treatment for diffuse large B‐cell lymphoma (DLBCL) …
prednisone) is a standard first‐line treatment for diffuse large B‐cell lymphoma (DLBCL) …
[Retracted] Preparation and Synergistic Anti‐Tumor Effect of Iridium Oxide Nanocomposites under Microscope
X He, F Xiang, Z Xu - International Journal of Analytical …, 2022 - Wiley Online Library
In order to solve the great difficulties in cancer prevention, diagnosis, and treatment, a
preparation method of iridium oxide nanocomposites under the microscope was proposed in …
preparation method of iridium oxide nanocomposites under the microscope was proposed in …
Ars2‐containing bispecific, Fab‐and IgG1‐format BAR‐bodies to target DLBCL cells
Despite recent advances in the therapy of diffuse large B‐cell lymphoma, not otherwise
specified (DLBCL), around 30% of patients develop refractory disease or relapse after first …
specified (DLBCL), around 30% of patients develop refractory disease or relapse after first …
Integrierung des B-Zell-Rezeptor-Antigens LRPAP1 in ein IgG1-Antikörperformat zur Therapie des Mantelzell-Lymphoms
K Olesch - 2021 - publikationen.sulb.uni-saarland.de
Das Mantelzell-Lymphom ist ein seltenes B-Zell-Non-Hodgkin-Lymphom. Es befällt vor
allem den älteren Mann mit einer geschlechterspezifischen Prävalenz von 3: 1 und einem …
allem den älteren Mann mit einer geschlechterspezifischen Prävalenz von 3: 1 und einem …